Skip to main content
. 2022 Nov 13;12(6):6488–6498. doi: 10.1002/cam4.5417

FIGURE 4.

FIGURE 4

Progression‐free survival associated with regorafenib monotherapy and regorafenib combined with a PD‐1 antibody in male patients without liver metastasis (A), female patients without liver metastasis (B), male patients with liver metastasis (C), and female patients with liver metastasis (D). Progression‐free survival associated with regorafenib monotherapy (E) and regorafenib combined with a PD‐1 antibody (F) grouped by sex and liver metastasis